Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New theory suggests treatment for Avian Influenza Infection

08.03.2006


Chemotherapy for a disorder of the immune system may - at least in theory - be effective against severe human avian influenza infection, this suggest scientists at the Karolinska Institutet.



The Hypothesis is published on online by The Lancet. The authors suggest that although chemotherapy for avian influenza is a substantial jump in thinking, such therapy could still be reasonable, particularly since it has been shown to be very effective in decreasing mortality in an immune disorder called haemophagocytic lymphohistiocytosis disease (HLH), which may be associated with severe infection by the Epstein-Barr virus.

The mortality rate for avian influenza A virus subtype H5N1 infection is around 50 percent, according to the World Health Organization, WHO, and there is an urgent need for novel treatments. In their Hypothesis professor Jan-Inge Henter at the Karolinska Institutet in Stockholm and colleagues in Hong Kong state that patients with H5N1 infection have some symptoms and post-mortem features in common with people with the immune disorder HLH. Patients with HLH have too many infection-fighting white blood cells, which can accumulate in good tissue and cause damage to a variety of organs. One of the key treatments for HLH is the chemotherapy drug etoposide, which helps kill the excess of immune cells.


The scientists emphasize that their suggestion at present merely is a hypothesis, and that the treatment not yet has been tested in patients affected by avian influenza infection.

- We would welcome the WHO to consider a platform for the undertaking of clinical trials based on a modified HLH protocol. including etoposide and corticosteroids, in addition to supportive and antiviral therapy for patients infected by H5N1, says professor Jan-Inge Henter.

Gustav Loefgren | alfa
Further information:
http://ki.se/ki/jsp/polopoly.jsp?d=130&a=10304&newsdep=130&l=en

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

Shape matters when light meets atom

05.12.2016 | Physics and Astronomy

Researchers uncover protein-based “cancer signature”

05.12.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>